Key result
Sacubitril/valsartan linked to recurrent hyponatremia that improves upon drug cessation in a cancer survivor.
Why the study?
Hyponatremia in cancer patients is common and multifactorial, and sacubitril/valsartan may cause clinically significant adverse effects complicating the management of heart failure and anticancer therapies.
Case Report (n=1)
Sacubitril/valsartan use may be associated with recurrent hyponatremia, highlighting the need for clinical suspicion in onconephrology patients.
Answers are grounded in this paper and cite their sources.
May indicate hyponatremia risk with sacubitril/valsartan in cancer survivors; hypothesis-generating and requires validation.
Hyponatremia in patients with cancer is common and often multifactorial, complicating the management of heart failure and anticancer therapies. Sacubitril/valsartan, a combined neprilysin inhibitor and angiotensin receptor blocker, is a cornerstone therapy for heart failure with reduced ejection fraction, but it may have adverse effects that are clinically significant. We present a case of a 54-year-old woman with poor-risk acute myeloid leukemia in remission after allogeneic hematopoietic stem cell transplantation who developed recurrent hyponatremia temporally associated with sacubitril/valsartan use. Cessation of the medication led to sodium improvement. This case highlights the need for increased clinical suspicion for drug-induced hyponatremia in onconephrology patients treated with neprilysin inhibitors.
No takes yet. Share an insight, caveat, or question.
LeMense et al. (2026) conducted a case report in Hyponatremia (n=1). Sacubitril/valsartan was evaluated on Recurrent hyponatremia. Sacubitril/valsartan use was temporally associated with recurrent hyponatremia in a 54-year-old cancer survivor, which improved upon cessation of the medication.
Synapse has enriched 10 related papers. Consider them for comparative context: